🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "major milestone" in the effort against superbug strains of the bacteria, according to researchers.

An International Health Concern

The sexually transmitted infection are escalating around the world, with estimates suggesting over 82 million new cases annually. Particularly high rates are reported in Africa and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely development in the context of rising global incidence, increasing antimicrobial resistance and the very limited treatment choices at this time.”

Health officials are particularly alarmed about the surge in treatment-resistant strains. The World Health Organization has designated it as a "priority pathogen". A tracking program showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

Zoliflodacin, alternatively called a brand name, was approved by the American regulatory agency in mid-December for treating gonorrhoea. This STI can lead to major issues, including infertility. Experts anticipate that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, gained clearance in the same week. This medication, which is also used to treat urinary tract infections, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a new, not-for-profit approach for drug creation. The non-profit organisation GARDP partnered with the drug firm its industry partner to bring it to fruition.

“This approval signifies a significant shift in the management of superbug gonorrhoea, which previously has been outpacing antibiotic development.”

Research Study Results and Global Access

According to results released by a prominent scientific publication, the new drug eradicated more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which involves two antibiotics. The study included hundreds of patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, the non-profit has the authority to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians treating patients have shared optimism. Having a single-dose, oral treatment of this kind is seen as a "critical tool" for public health efforts. This is deemed essential to alleviate the strain of the disease for people and to stop the proliferation of highly drug-resistant gonorrhoea around the world.